Marketwired .

Subscribe to Marketwired .: eMailAlertsEmail Alerts
Get Marketwired . via: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

News Feed Item

NicOx presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc.

NicOx presents preclinical results at AHA from antihypertensive collaboration with Merck & Co., Inc.

Sophia Antipolis Cedex -- (MARKET WIRE) -- 11/14/06 -- November 14, 2006. Sophia Antipolis, France. www.nicox.com

NicOx S.A. (Eurolist: NICOX) today announced that very good preclinical results on a prototype compound from its ongoing research collaboration with Merck & Co., Inc. (NYSE: MRK) were reported by the two companies yesterday in an oral presentation at the American Heart Association (AHA) Scientific Sessions 2006, in Chicago. These results suggest that NicOx' proprietary nitric oxide-donating technology may have the potential to improve the blood pressure lowering activity of antihypertensive agents.

Ennio Ongini, Vice President of Research at NicOx, commented: "We were honored to present these very encouraging results together with Merck at the American Heart Association meeting. These findings validate the concept of using nitric oxide-donation to augment the efficacy of existing anti-hypertensive agents. We are making good progress in our collaboration and both NicOx and Merck are working hard to advance a candidate into the clinic at the earliest possibility."

Enalapril, a common anti-hypertensive drug and equimolar doses of NCX 899, a nitric oxide-donating derivative of enalapril, were studied in aged spontaneously hypertensive rats, a validated model of hypertension. NicOx and Merck consider NCX 899 as a prototype compound for demonstrating the increased activity of nitric oxide- donating antihypertensive agents. The compounds were administered orally, once daily, for 7 consecutive days, and blood pressure was measured by continuous 24-hour telemetry monitoring. NCX 899 produced a statistically significant better reduction in systolic blood pressure compared to enalapril when measured on day 7, between 2 and 6 hours post dosing (p < 0.05). NCX 899's blood pressure lowering activity was sustained over the full 7-day administration schedule showing that the nitric oxide-donation of NCX 899 did not induce tolerance. NCX 899 and enalapril caused a similar degree of ACE inhibition. However NCX 899 was associated with a statistically significant increase of basal plasma nitrate/nitrate levels compared to enalapril, suggesting that the sustained and improved activity of NCX 899 is due to nitric oxide donation.

NicOx (Bloomberg: COX.FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of pain and inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 development for the treatment of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext Paris (segment: Next Economy).

The elements included in this communication may contain forward- looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's document de reference.

CONTACTS: NicOx: Karl Hanks - Manager of Corporate Relations and Market Analysis - Tel +33 (0)4 97 24 53 42 - hanks@nicox.com - www.nicox.com

Investors in the United States - Burns McClellan: Lisa Burns - lburns@burnsmc.com / Laura Siino- lsiino@burnsmc.com - Tel +1 212 213 0006

Financial Dynamics: Jonathan Birt - Tel +1 212 850 56 34 - jbirt@fd-us.com / Julia Phillips - Tel +44 (0)20 7831 3113 - julia.phillips@fd.com

NicOx S.A.,

Les Taissounières - Bât HB4 - 1681 route des Dolines - BP313, 06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 -

Fax +33 (0)4 97 24 53 99

This information is provided by CompanynewsGroup

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.